medcelerator · clinician one-pager
New Daily Pill for Advanced Breast Cancer After Hormone Therapy
Veppanu (vepdegestrant) — first FDA-approved PROTAC for ESR1-mutated ER+/HER2− advanced breast cancer
FDA Approved · United States · September 7, 2026
Condition: Breast Cancer
Who this is for
Veppanu (vepdegestrant) is a daily pill. The United States approved it for adults with estrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 gene mutation, after earlier hormone therapy.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/veppanu-vepdegestrant